Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries
Open Access
- 15 November 2020
- journal article
- review article
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 14 (6) , 685-698
Abstract
Rupa Banerjee, Raja Affendi Raja Ali, Shu Chen Wei, and Shashi Adsul. Gut and Liver 2020;14:685-98. https://doi.org/10.5009/gnl19209Keywords
This publication has 71 references indexed in Scilit:
- Anti-TNF immunotherapy reduces CD8+ T cell–mediated antimicrobial activity against Mycobacterium tuberculosis in humansJournal of Clinical Investigation, 2009
- LTBI: latent tuberculosis infection or lasting immune responses toM. tuberculosis? A TBNET consensus statementEuropean Respiratory Journal, 2009
- Tumor Necrosis Factor Blockers Influence Macrophage Responses toMycobacterium tuberculosisThe Journal of Infectious Diseases, 2008
- Effectiveness of the combination of a whole‐blood interferon‐gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapyArthritis Care & Research, 2008
- Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2008
- Diagnosis of Crohn’s disease in India where tuberculosis is widely prevalentWorld Journal of Gastroenterology, 2008
- Clinical experience with infliximab among Filipino patients with rheumatic diseasesInternational Journal of Rheumatic Diseases, 2006
- Experience with anti-tumor necrosis factor-α therapy in IndiaInternational Journal of Rheumatic Diseases, 2006
- The Montreal classification of inflammatory bowel disease: controversies, consensus, and implicationsGut, 2006
- BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF- treatmentThorax, 2005